Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback